CoChat

Heads on! Designing a Qualification Framework for Organ-on-Chip

Open access

The DOI matches its Crossref record; 4 of the 6 references it cites were found in a registry or an index.

Abstract

Expert feedbackThe key starting point for obtaining regulatory uptake of an OoCbased method is a clear definition of its intended context of use (CoU).Only when the CoU is fully described and understood, does it make sense to start pursuing qualification in a meaningful way.Most OoC models have been developed for biomedical research purposes rather than regulatory applications, thus developers and end-users have to adapt these models and figure out how to use them to address regulatory information requirements.As an example, the same liver OoC model could in principle be used in a preclinical setting to evaluate the metabolic biotransformation of a new drug candidate, its pharmacological efficacy, or its potential to induce liver injury.These represent three general but distinct CoUs, which address different questions that a regulator may have.More refined descriptions of CoU also specify aspects such as therapeutic target group, population variability, and anticipated off-target pharmacology.In addition, CoU includes an indication of what other information sources are used in conjunction with the OoC-derived information, and in that frame, how the OoC results can be interpreted to arrive at a conclusion.In the preclinical assessment of new drug candidates, the context in which efficacy is assessed differs significantly with respect to the assessment of safety.Within the former, the pharmacological effect is already known and thus only therapeutically targeted organs need to be considered.For the latter however, potential off-target effects in non-target organs have to be accounted for, which typically makes it more challenging to employ a single OoC for safety assessment.When devising qualification strategies for OoC methods used in efficacy or safety studies, the relevant exposure scenario has to be considered, including the nominal dose, the route of exposure (e.g., dermal, inhalation or oral), and whether the drug is administered once or repeatedly over a period of time.For efficacy assessment, the comparative standard is usually the treatment applied in clinical practice, thus in-vivo-to-in-vitro extrapolation and related allometric-type scaling are required to ensure an equivalent internal dosing scenario within the OoC model.A satisfactory level of qualification can only be achieved with a sufficient level of standardization, and vice versa.Thus, the development of OoC qualification frameworks and associated criteria should both reflect and influence ongoing efforts to address standardization of OoC (Piergiovanni et al., 2021a,b).Standards

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.14573/altex.2401231

Cites

0 citation errors · 2 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

The publisher hasn’t deposited this paper’s reference list.

Research works printed but not linked: 1

  1. Tomlinson, L., Ramsden, D., Leite, S. B. et al. (2023). Consid- erations from an international regulatory and pharmaceutical industry (IQ MPS Affiliate) workshop on the standardization

Cited by

Metadata

Authors
Piergiovanni, M., Mennecozzi, M., Sampani, S. I., & Whelan, M.
Affiliations
Joint Research Centre (IT)
Venue
ALTEX
Publisher
ALTEX Edition
Published
2024
Volume
41
Issue
2
Pages
320-323
ISSN
0946-7785 (ISSN-L)
OpenAlex
W4392251231
Cited by
5
References
0
Citations by year
2025: 2 · 2024: 3
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • ALTEX (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Bundesinstitut für Arzneimittel und Medizinprodukte
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
  • Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
Keywords
organ-on-a-chip, qualification frameworks, regulatory acceptance, context of use, liver-on-a-chip, drug safety assessment, drug efficacy evaluation, allometric scaling, standardization, drug-induced liver injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.